Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cannara Biotech's gross profit for the
three
months ended in May. 2026 was $10.96 Mil. Cannara Biotech's gross profit for the trailing twelve months (TTM) ended in May. 2026 was $36.23 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Cannara Biotech's gross profit for the
three
months ended in May. 2026 was $10.96 Mil. Cannara Biotech's Revenue for the
three
months ended in May. 2026 was $23.20 Mil. Therefore, Cannara Biotech's Gross Margin % for the quarter that ended in May. 2026 was 47.23%.
Cannara Biotech had a gross margin of 47.23% for the quarter that ended in May. 2026 => Durable competitive advantage
During the past 8 years, the highestGross Margin % of Cannara Biotech was 80.73%. The lowest was 36.44%. And the median was 47.98%.
Warning Sign:
Cannara Biotech Inc gross margin has been in long-term decline. The average rate of decline per year is -5.5%.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Cannara Biotech had a gross margin of 47.23% for the quarter that ended in May. 2026 => Durable competitive advantage
Cannara Biotech Gross Profit Related Terms
Cannara Biotech Gross Profit Historical Data
* Premium members only.
The historical data trend for Cannara Biotech's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cannara Biotech's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cannara Biotech Gross Profit vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cannara Biotech's Gross Profit distribution charts can be found below:
* The bar in red indicates where Cannara Biotech's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $36.23 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Cannara Biotech (LOVFF) has a Gross Profit of $36.23 Mil as of May. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on Cannara Biotech and its competitors.
Is Cannara Biotech's Gross Profit too high?
Cannara Biotech's current Gross Profit is $36.23 Mil. Overall, Cannara Biotech has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cannara Biotech's Gross Profit compare to ZTS?
Cannara Biotech's Gross Profit of $36.23 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Drug Manufacturers company?
A good Gross Profit depends on the Drug Manufacturers industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Cannara Biotech and its competitors. Cannara Biotech's current Gross Profit is $36.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannara Biotech stock overvalued right now?
Based on GuruFocus' analysis, Cannara Biotech (LOVFF) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.22, compared to a current price of $1.45 — trading 18.9% above its estimated fair value. The current Gross Profit is $36.23 Mil. Cannara Biotech's overall GF Score™ is 88/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Cannara Biotech (LOVFF), the current Gross Profit is $36.23 Mil as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cannara Biotech (LOVFF) Overvalued in 2026?
Based on GuruFocus' analysis, Cannara Biotech stock appears to be overvalued.
The current stock price of $1.45 is trading 18.9% above its estimated GF Value™ of $1.22.
GuruFocus considers Cannara Biotech to be Modestly Overvalued.
Key valuation signals for LOVFF:
Gross Profit: $36.23 Mil
GF Value™: $1.22 vs. price of $1.45 (18.9% above fair value)
No single metric tells the full story. See the LOVFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .
88GF Score
Get the complete analysis for LOVFF
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LOVFF has been successfully added to your 
